Authors
Samiea, A., Bahn-Bales, R., Vanderstreet, J., Al-Ghezi, M., Gao, L., Rettig, M., Guo, Z., Yadav, R., Herzig, D. O., Fang, S. H., Tsikitis, L., Kardosh, A., Rodda, L. B., Pucci, F., Yu, W. Y., Duhen, R., Moreau, J. M.
Abstract
Tissue-resident memory B cells (BRM) provide powerful localized protection against microbial infection in barrier tissues. It is unknown if analogous BRM populations survey solid tumors and contribute to anti-cancer immunity. We profiled B cells from patients with colorectal cancer and cutaneous basal cell carcinoma and identified a CD69 memory B cell population consistent with a tissue-resident phenotype. Integrative analysis of transcriptomic datasets identified an optimized signature enriched across cancer types. Tumor infiltrating BRM-like cells preferentially exhibited autoreactivity and their signature correlated with patient outcomes and response to immunotherapy. Skin and lung targeted vaccination established localized BRM that provided IgA dependent organ specific protection upon tumor challenge in murine models. These findings establish BRM as an active component of anti-cancer immunity via preferential reactivity to tumor associated self-antigens.
Preprint server:
bioRxiv
The authors list and abstract were imported from bioRxiv on 14 Aug 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0